West Pharmaceutical Services, Inc
West Pharmaceutical Services is a U.S.-based manufacturer of containment and delivery systems used with injectable drugs and healthcare products. Its business spans proprietary packaging and drug-delivery components, contract manufacturing, analytical lab services, and integrated solutions for pharmaceutical, biologic, diagnostic, and medical device customers worldwide.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueProprietary packaging, containment, and drug-delivery components for injectable therapies.
Design, manufacture, and automated assembly of complex devices and components for customers.
Customers
West sells to pharmaceutical, biologic, generic, diagnostic, and medical device companies that need components or outsourced manufacturing for injectable and device-based products. Customers buy West’s systems to support product compatibility, regulatory compliance, sterile handling, and efficient delivery to patients. A small number of large customers account for a meaningful share of revenue, making customer concentration an important feature of the business.
Buy containment and delivery systems for injectable biologics and specialty therapies; they value quality, compatibility, and regulatory support.
Buy packaging components, transfer systems, and delivery devices for injectable medicines and line integration.
Buy contract-manufactured components and assembled devices for further processing or end-use products.
High-volume customers that purchase across both proprietary and contract-manufacturing segments.
Strategy
West’s strategy centers on being a full-service supplier of high-quality injectable drug containment and delivery systems, supported by engineering, analytical, and regulatory expertise. It also emphasizes global manufacturing flexibility, multi-site production, and automated assembly capabilities to serve large pharmaceutical customers and complex programs. The company’s position depends on innovation in drug-delivery technologies and on maintaining trusted relationships with customers that value reliability and technical support.
Customers want suppliers that can combine packaging, device, and technical support in one platform.
Multinational customers value supply continuity and local production options.
Innovation helps defend against commoditization and alternative delivery formats.
Automation supports complex device production and competitive cost structure.
Geography
2025West operates as a global business with manufacturing, sales, and support activities across the United States and many international markets. The company also maintains collaborations in Japan and Mexico, and it holds a substantial portion of cash outside the U.S., reflecting its international operating footprint. Geography matters because customer demand, tariffs, currency movements, and local regulatory requirements can affect sourcing, production, and sales execution.
Share of the revenue the company reports by geography.
Risks
West faces customer concentration, pricing pressure, and intense competition across both proprietary components and contract manufacturing. Its results also depend on continued demand for injectable therapies, while international operations expose it to tariffs, supply disruptions, currency effects, and local regulatory complexity. Accounting and valuation risk is meaningful because goodwill, long-lived assets, and inventory levels depend on assumptions about future demand and cash flows.
- Customer concentrationImpact: HighLikelihood: Medium
Ten customers represented a large share of consolidated sales, so account loss or volume shifts can materially affect revenue.
Exposure: One customer exceeded 10% of sales
- Pricing pressureImpact: HighLikelihood: Medium
Large pharmaceutical customers and competitors can force lower prices or tougher contract terms.
Exposure: Both proprietary and contract-manufacturing segments
- Shift away from injectable therapiesImpact: HighLikelihood: Medium
The business depends on products delivered by injection; alternative delivery methods could reduce demand.
Exposure: GLP-1 and other injectable drug programs
- International trade and regulatory exposureImpact: MediumLikelihood: Medium
Operations span multiple countries, creating exposure to tariffs, customs controls, and local compliance requirements.
Exposure: Global manufacturing and sales network
- Impairment risk on goodwill and long-lived assetsImpact: MediumLikelihood: Medium
Valuations depend on future cash flows, product demand, and innovation success.
Exposure: Reporting units and manufacturing assets
Accounting
Judgemental itemsSales mix, order timing, and shipment timing can shift revenue between periods across segments and geographies.
Impact: Quarterly comparability
Valuation depends on future demand for injectable products and new-product innovation.
Impact: Could create material non-cash charges
Manufacturing assets are tested when demand weakens or strategy changes.
Impact: May affect operating results and asset values
The company carries inventory and raw-material commitments to support customer demand.
Impact: Working capital and supply-chain exposure
Global operations create hedge and translation effects that can move reported balances.
Impact: Earnings and balance-sheet volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
Elite Pharmaceuticals Inc /NV/
ELTP · Pharmaceutical Preparations
Elite Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc.
AMPH · Pharmaceutical Preparations
Zymeworks Inc.
ZYME · Pharmaceutical Preparations
Bio Green Med Solution, Inc.
BGMSP · Wholesale-Durable Goods, NEC
Waters Corporation
WAT · Laboratory Analytical Instruments
Waters Corp.
Teva Pharmaceutical Industries Limited
TEVA · Pharmaceutical Preparations
Last updated: 24/09/2026